Progress in cancer chemotherapy with special stress on molecular-targeted therapy

Japanese Journal of Clinical Oncology

Volumn 40, Issue 9, 2010, Pages 855-862

  Saijo, Nagahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Molecular targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BEVACIZUMAB; CAMPTOTHECIN; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; LENALIDOMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROVENGE; RITUXIMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; THALIDOMIDE; TRASTUZUMAB; TUMOR MARKER; VANDETANIB; VINCA ALKALOID; ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; COLORECTAL CANCER; CYTOTOXICITY; DRUG EFFICACY; GENE MUTATION; KIDNEY CANCER; LARGE INTESTINE CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MYELOMA; OVARY CARCINOMA; PHARMACOGENOMICS; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; STOMACH CANCER; SURGICAL PATIENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG THERAPY; HUMAN; METABOLISM; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956157674     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq035     Document Type: Article

References (52)

1. Saijo N. Molecular targeted therapy for lung cancer: recent topics. J Lung Cancer 2008;7:1-8.
2. Saijo N. Advances in the treatment of non-small cell lung cancer. Cancer Treat Rev 2008;34:521-6.
3. Eisenhauer E, Therasse P, Bogaerls J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effect of a selective inhibitor of the all tyrosine kinase on the growth of Bcr-abl positive cells. Nat Med 1996;2:561-6.
5. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positsive lung cancer. Proc Natl Acad Sci USA 2008;105:19893-7.
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of EML4-ALK fusion gene in small cell lung cancer. Nature 2007;448:561-6.
7. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutation in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
9. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of tyrosine kinase inhibitor STI571 in patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
10. Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol 2009;6:287-94.
11. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
12. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-P185 Her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic Breast cancer. J Clin Oncol 1996;14:737-44.
13. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2 antibody enhances the antitumor activity of paclitaxel and doxorubicin against Her2/neu over expressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over express HER2. New Engl J Med 2001;344:783-92.
15. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predicts gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 2005;23:6829-37.
16. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the EGFR gene predicts prolonged survival after gefitinib treatment in patients with NSCLC with post operative recurrence. J Clin Oncol 2005;23:2513-20.
17. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, et al. Gefitinib combined survival analysis of the mutation positive NSCLC from the prospective phase II trials (I CAMP). Clin Cancer Res 2009;15:4493-98.
18. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
19. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, et al. First line gefitinib versus first line chemotherapy by CBDCA plus PTL in non-small cell lung cancer patients with EGFR mutations, a phase III study by North East Japan Gefitinib Study Group. J Clin Oncol 2009;27:Abstract 8016.
20. Fong PC, Boss DS, Carden CP, Roelvink M, De Greve J, Gourley CM, et al. AZD2281, a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer; results from a phase I study. J Clin Oncol 2008;27:5510.
21. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, et al. Phase II trial of the oval PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27(Suppl.): 18s.
22. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201 a poly ADP-ribose polymerase-1 (PARP 1) inhibitor, in combination with gemcitabine/carboplatin (GC) in patients with metastatic triple-negative breast cancer. Results of a randomized phase III trial. J Clin Oncol 2009;27:3.
23. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-42.
24. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study D3200. J Clin Oncol 2007;25:1539-44.
25. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
26. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
27. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:1227-34.
28. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007;370:2103-11.
29. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23: 792-9.
30. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
31. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC); AVADO. J Clin Oncol 2008;26(Suppl.):Abstract LBA1011.
32. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl.):Abstract 1005.
33. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
34. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;3007:58-62.
35. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
36. Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2009;27(Suppl.):Abstract LBA4.
37. Bender RA, Knauer M, Rutgers EJ, Glas AM, de Snoo FA, Linn SC, et al. The 70 gene profile and chemotherapy benefit in 1,600 cancer patients. J Clin Oncol 2009;27:512.
38. Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery IC, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage III colon cancer: selection of the genes in four large studies and results of independent prospectively designed QUASAR validation study. J Clin Oncol 2009;27:4000.
39. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
40. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT 1A1 genetic polymorphisms in Japanese: roles of UGT1A1 6 and 28. Pharmacogenet Genomics 2007;17:497-504.
41. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology 2003;17:52-5.
42. Ratain M. From bedside to band to bedside to clinical practice: an Odyssey with irinotecan. Clin Cancer Res 2006;12:1658-60.
43. Simon R. Road map for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23:7332-41.
44. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small cell lung cancer. J Clin Oncol 2007;25:2741-6.
45. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5.
46. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
47. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRMI and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.
48. Solia JC. ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. J Clin Oncol 2007;5:2648-9.
49. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. IALT Bio Investigators. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
50. Guidance for industry, investigators, and reviewers: exploratory IND studies. FDA January 2006 Pharmacology and Toxicology. http://www.fda.gov/CDER/guidance/7086fnl.htm.
51. Biomakers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
52. Simon R. Development and validation of therapeutically relevant multigene biomarker classifiers. J Natl Cancer Inst 2005;97:866-7.